Drug for rare form of ALS, based in part on WashU research, approved by FDA - The Source

A new drug has been approved by the Food and Drug Administration (FDA) for a rare, inherited form of amyotrophic lateral sclerosis (ALS). Called tofersen, the drug — developed by Biogen Inc. and based in part on research conducted at Washington University School of Medicine in St. Louis — slows the progression of the deadly, paralyzing disease.

Related Keywords

Massachusetts ,United States ,Lou Gehrig ,Robert Bucelli ,Seanm Healey ,Timothym Miller ,School Of Medicine ,Ionis Pharmaceuticals ,Washington University ,Drug Administration ,Biogen Inc ,Washington University School Of Medicine ,Washington University School ,David Clayson Professor ,Merit Cudkowicz ,Massachusetts General Hospital ,